News | August 07, 2012

Navidea Biopharmaceuticals Licenses Parkinson's Imaging Agent

Licensing adds second promising neuroimaging candidate to Navidea pipeline

August 7, 2012 — Navidea Biopharmaceuticals Inc., a company focused on precision diagnostic radiopharmaceuticals, announced it has entered into an agreement with Alseres Pharmaceuticals Inc. to license [123I]-E-IACFT Injection (CFT), an iodine-123 radio-labeled imaging agent being developed as an aid in the diagnosis of Parkinson’s disease and other movement disorders, with a potential use as a diagnostic aid in dementia.

CFT is a patented, novel, small molecule radiopharmaceutical used with single photon emission computed tomography (SPECT) imaging to identify the status of specific regions in the brains of patients suspected of having Parkinson’s disease. The agent binds to the dopamine transporter (DAT) on the cell surface of dopaminergic neurons in the striatum and substantia nigra regions of the brain. Loss of these neurons is a widely recognized hallmark of Parkinson’s disease.

CFT has been administered to more than 600 subjects in multiphase clinical trials to date. Results from these clinical trials have demonstrated that CFT has high affinity for DAT and rapid kinetics that enable the generation of clean diagnostic images quickly, beginning within approximately 20 minutes after injection. In addition to its potential use as an aid in the differential diagnosis of Parkinson’s disease and movement disorders, CFT may also be useful in the diagnosis of dementia with Lewy bodies (DLB), which, after Alzheimer’s disease, is one of the most common forms of dementia.

“The diagnostic dilemma in movement disorders remains a pressing medical need that will continue to escalate as our world’s population ages,” said Mark Pykett, president and CEO of Navidea. “The addition of the CFT program is consistent with our growth strategy to build our precision radiopharmaceutical pipeline with later-stage, high-value diagnostics aimed at important medical needs.”

“We believe that CFT has the potential to be a best-in-class imaging agent to improve diagnostic accuracy by differentiating Parkinson’s disease from non-degenerative movement disorders, especially during the period soon after symptom-onset,” said Thomas Tulip, executive vice president and chief business officer at Navidea. “This licensing agreement has afforded Navidea another strong Phase 3 diagnostic imaging asset that has great synergy with our AZD4694 imaging program, which we are developing as an aid in the diagnosis of Alzheimer’s disease. These exciting programs provide us with a robust franchise in precision neuroimaging diagnostics.”

Under the terms of the license agreement, Alseres granted Navidea an exclusive, worldwide sub-license to research, develop and commercialize CFT. The final terms of the agreement call for Navidea to make a one-time sub-license execution payment to Alseres equal to $175,000 and issue Alseres 300,000 shares of NAVB common stock.

For more information: www.navidea.com

Related Content

Book Chapter Reports on Fonar Upright MRI for Hydrocephalus Imaging

Rotary misalignment of atlas (C1) and axis (C2). Image courtesy of Scott Rosa, DC, BCAO.

News | Magnetic Resonance Imaging (MRI) | March 20, 2019
Fonar Corp. reported publication of a chapter where the physician-author-researchers utilized the Fonar Upright Multi-...
Gregory W. Albers, M.D., Receives Distinguished Clinical Research Achievement Award for Stroke Research
News | Stroke | March 19, 2019
iSchemaView announced the company’s co-founder Gregory Albers, M.D., has received the Distinguished Clinical Research...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
New MRI Sensor Can Image Activity Deep Within the Brain
News | Magnetic Resonance Imaging (MRI) | March 15, 2019
Calcium is a critical signaling molecule for most cells, and it is especially important in neurons. Imaging calcium in...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Iron Measurements With MRI Reveal Stroke's Impact on Brain

Images show illustrative examples of visual R2? modifications within substantia nigra (SN) at baseline (24-72 h) and follow-up (1 y) in striatum (participants 1 and 2) and control groups (participants 3 and 4). Image courtesy of the Radiological Society of North America (RSNA).

News | Stroke | March 12, 2019
March 12, 2019 — A simple ...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
iSchemaView Launches RAPID Angio
Technology | Angiography | March 01, 2019
iSchemaView announced the release of RAPID Angio, a complete neuroimaging solution for the angiography suite that...
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with...